Olympus12.15.21
Olympus and Medivators terminated pending patent infringement action brought by Olympus in March 2021 regarding the AmplifEYE products. The settlement resolves the pending action before the Texas court alleging Medivators’ infringement of two of Arc Medical’s patents. Medivators has announced it will cease the sale or distribution of AmplifEYE products after December 31. The specific terms of the agreement remain confidential. Arc Medical is a subsidiary of Olympus Corporation.
“We are pleased with the terms of this settlement as it demonstrates Olympus Corporation’s commitment to invest in and defend its intellectual property throughout the world,” said Gael Tisack, Global Head of Intellectual Property for Olympus Corporation.
Arc Medical’s patented ENDOCUFF device is an assistive technology for colonoscopy that has been shown to increase the rate of adenoma detection by as much as 11 percent compared to standard colonoscopy.1 Research shows for every 1 percent increase in ADR, there is a 3 percent reduction in the risk of interval colorectal cancer and a 5 percent reduction in the risk of fatal colorectal cancer (CRC).2 Higher detection rates and more accurate diagnosis through screening can reduce the number of deaths from preventable digestive cancers, such as colorectal cancer, which is a leading cause of cancer death for both men and women worldwide.3
Attaching to the distal end of a colonoscope, the flexible ENDOCUFF arms smooth the large folds of the mucosa lining the colon, allowing the physician to inspect more of the mucosal surface area for abnormalities. The action of the ENDOCUFF arms also anchor the scope tip during loop reduction and stabilize the scope tip during complex procedures, such as a polypectomy.
References
1 Williet N, Tournier Q, et al. Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials. Endoscopy. 2018;50(9):846-860. doi: 10.1055/a-0577-3500.
2 Corley DA, Jensen CD, Marks AR, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. N Engl J Med. 2014;370:1298-1306. doi: 10.1056/NEJMoa1309086.
3 American Cancer Society. Key statistics for colorectal cancer. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html. Accessed December 10, 2021.
4 Patel HK, Chadrasekar VT, Srinivasan S, et al. Second-generation distal attachment cuff improves adenoma detection rate: meta-analysis of randomized controlled trials. Gastrointest Endosc. 2020;93(3):544-553.e7. doi: 10.1016/j.gie.2020.09.045.
“We are pleased with the terms of this settlement as it demonstrates Olympus Corporation’s commitment to invest in and defend its intellectual property throughout the world,” said Gael Tisack, Global Head of Intellectual Property for Olympus Corporation.
Arc Medical’s patented ENDOCUFF device is an assistive technology for colonoscopy that has been shown to increase the rate of adenoma detection by as much as 11 percent compared to standard colonoscopy.1 Research shows for every 1 percent increase in ADR, there is a 3 percent reduction in the risk of interval colorectal cancer and a 5 percent reduction in the risk of fatal colorectal cancer (CRC).2 Higher detection rates and more accurate diagnosis through screening can reduce the number of deaths from preventable digestive cancers, such as colorectal cancer, which is a leading cause of cancer death for both men and women worldwide.3
Attaching to the distal end of a colonoscope, the flexible ENDOCUFF arms smooth the large folds of the mucosa lining the colon, allowing the physician to inspect more of the mucosal surface area for abnormalities. The action of the ENDOCUFF arms also anchor the scope tip during loop reduction and stabilize the scope tip during complex procedures, such as a polypectomy.
References
1 Williet N, Tournier Q, et al. Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials. Endoscopy. 2018;50(9):846-860. doi: 10.1055/a-0577-3500.
2 Corley DA, Jensen CD, Marks AR, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. N Engl J Med. 2014;370:1298-1306. doi: 10.1056/NEJMoa1309086.
3 American Cancer Society. Key statistics for colorectal cancer. https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html. Accessed December 10, 2021.
4 Patel HK, Chadrasekar VT, Srinivasan S, et al. Second-generation distal attachment cuff improves adenoma detection rate: meta-analysis of randomized controlled trials. Gastrointest Endosc. 2020;93(3):544-553.e7. doi: 10.1016/j.gie.2020.09.045.